Status:
COMPLETED
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Inje University
Pacific Pharmaceuticals
Conditions:
Helicobacter Infection
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
At present, triple therapy are recommended by various guidelines for the treatment of Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment failure rates with o...
Eligibility Criteria
Inclusion
- H. pylori infection
- Aged between 18-80 years
- Are willing to received eradication therapy for H. pylori
Exclusion
- Children and teenagers aged less than 18 years or over 80 years
- Previous eradication therapy for H. pylori
- History of gastrectomy
- Previous allergic reaction to antibiotics
- Use of prompt pump inhibitors and antibiotics in the recent 4 weeks
- Active upper GI bleeding in the recent 1 week
- Contraindication to treatment drugs
- Pregnant or lactating women
- Severe concurrent disease or malignancy
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT00841854
Start Date
June 1 2008
End Date
November 1 2010
Last Update
December 6 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736